8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 2, 2008

SCHERING-PLOUGH CORPORATION

(Exact Name of Registrant as Specified in its Charter)

New Jersey
(State or Other Jurisdiction
of Incorporation) 1-6571
(Commission
File Number) 22-1918501
(IRS Employer
Identification No.)

2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
	Item 9.01. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EX-99.1: PRESS RELEASE

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective January 2, 2008, the Board of Directors of Schering-Plough Corporation elected Dr. Craig B. Thompson as a member of the Board of Directors.

A press release dated January 3, 2008 related to Dr. Thompson’s appointment is attached as Exhibit 99.1

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT NO.		DESCRIPTION
	99.1	Press Release, dated January 3, 2008, entitled “Schering-Plough Board Elects Dr. Craig B. Thompson as a Director.”

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Schering-Plough Corporation

By: /s/ Susan Ellen Wolf

Susan Ellen Wolf
Corporate Secretary,
Vice President — Corporate Governance and
Associate General Counsel

Date: January 3, 2008

EXHIBIT INDEX

Exhibit
Number		Description
	99.1	Press Release, dated January 3, 2008, entitled “Schering-Plough Board Elects Dr. Craig B. Thompson as a Director.”

EX-99.1

Exhibit 99.1

FOR RELEASE: IMMEDIATELY	Media Contact:	Steve Galpin, Jr.
		(908) 298-7415
	Investor Contacts:	Alex Kelly
		Robyn Brown
		(908) 298-7436

Schering-Plough Board Elects Dr. Craig B. Thompson as a Director

KENILWORTH, N.J., Jan. 3, 2008 — Schering-Plough Corporation (NYSE: SGP) today announced that its Board had elected Dr. Craig B. Thompson as a member of its Board of Directors, effective Jan. 2, 2008. Dr. Thompson is Director of the Abramson Cancer Center and Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia.

     Dr. Thompson is an independent director under both the New York Stock Exchange standards and the more restrictive Schering-Plough Board independence standards.

     Dr. Thompson, 54, earned an M.D. from the University of Pennsylvania School of Medicine and an AB from Dartmouth College. He chairs the Medical Advisory Board at the Howard Hughes Medical Institute, serves on the advisory boards of St. Jude Children’s Research Hospital and M.D. Anderson Cancer Center, and participates in a number of other professional and civic activities.

     “Craig’s perspective as a scientist and physician will add significant strength to our work as a Board,” said Patricia F. Russo, Chair of the Board’s Nominating and Corporate Governance Committee. “We are pleased to continue to increase the collective knowledge of the Board with this new member.”

     “Craig brings deep experience to our Board in the fields of medicine, medical research and fighting cancer, an important priority for humankind. This additional strength on the Board is critical as we continue to increase Schering-Plough’s science-focus during our progression along our Action Agenda to transform Schering-Plough into a high-performance, global competitor for the long term,” said Fred Hassan, Schering-Plough chairman and chief executive officer.

     Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company’s ongoing transformation. Schering-Plough’s vision is to “Earn Trust, Every Day” with

- more -

- 2 -

the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

# # #